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Abstract
Objective To compare the risk of cervical cancer in women with
histologically confirmed cervical intraepithelial neoplasia who returned
to routine screening after having completed post-treatment follow-up
with consecutive normal smear test results with women with a normal
primary smear test result.
Design Population based cohort study using data from a nationwide
pathology register.
Setting The Netherlands, 1994 to 2006.
Population 38 956 women with histologically confirmed intraepithelial
neoplasia grades 1 to 3 with completed follow-up after treatment.
Intervention Routine post-treatment follow-up of cervical intraepithelial
neoplasia, recommending smear tests at six, 12, and 24 months.
Main outcomemeasure Incidence of cervical cancer in the period from
completed follow-up with negative test results after cervical intraepithelial
neoplasia to the next primary test. 10-year hazard ratios were compared
with periods after normal results for the primary smear test, adjusted for
year in follow-up.
Results 20 cervical cancers were diagnosed during 56 956 woman
years after completed follow-up of cervical intraepithelial neoplasia,
whereas 1613 cervical cancers were diagnosed during 25 020 697
woman years after a normal primary smear test result. The incidence of
35.1 (95% confidence interval 21.4 to 54.2) per 100 000 woman years
and 6.4 (6.1 to 6.8) per 100 000 woman years, respectively, led to an
adjusted hazard ratio of 4.2 (95% confidence interval 2.7 to 6.5) for
periods after completed follow-up compared with periods after normal
primary smear test results. This hazard ratio was increased for all ages.
No significant difference in risk of cervical cancer was observed by grade
of cervical intraepithelial neoplasia.
Conclusions An excess risk of cervical cancer previously observed for
women treated for cervical intraepithelial neoplasia was also observed
in the subgroup of women who completed their post-treatment follow-up
with three consecutive normal smear test results. The overall corrected
risk of cervical cancer in these women was increased fourfold 35 cases
per 100 000 woman years) compared with women with normal primary
smear test results (6 per 100 000 woman years).
Introduction
The aim of cervical screening is to reduce the incidence of and
mortality from cervical cancer. This is predominantly achieved
by identifying and treating cervical intraepithelial neoplasia.
Although treatment is highly effective,1 affected women remain
at higher risk of cervical cancer than women in the general
population.2-6Consequently, follow-up after treatment to identify
residual and recurrent lesions is usually recommended.
The intensity of follow-up testing after treatment for cervical
intraepithelial neoplasia varies by country. For example, biennial
testing for 25 years is recommended in Sweden,7 and yearly
testing for 20 years is recommended in the United States,8 for
10 years in the United Kingdom,9 and for two years in
Denmark,10 Slovenia,11 and the Netherlands.12 The piloted
scheme in the United Kingdom now recommends follow-up
with cytology and testing for human papillomavirus six months
after treatment.13 In general, women with normal smear test
results at follow-up are recommended to resume routine
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screening, with intervals varying between three and five years
in most European countries.14 This is the same recommendation
as for womenwith a normal primary smear test result, and would
imply that after negative test results during post-treatment
follow-up the risk is back to “normal.” However, little is known
about whether this is the case.5 15 This can be tested only with
detailed data, which are often not available.
We determined the risk of cervical cancer in women with
histologically confirmed cervical intraepithelial neoplasia who
completed post-treatment follow-up with negative test results
according to one of the internationally least intensive follow-up
recommendations—those of the Netherlands, compared with
the risk in women with a normal primary smear test result. The
analysis was based on highly complete national histopathology
and cytopathology data from the Netherlands.
Methods
Recommendations for follow-up in the
Netherlands
In the Netherlands, women with primary smear test results
showingmoderate or severe dyskaryosis, as well as womenwith
smear test results showing persistent borderline or mild
dyskaryosis are referred for colposcopy. Women with
histologically confirmed cervical intraepithelial neoplasia grade
1 are recommended to have a colposcopy and a smear test in
12 months and are treated if particular conditions are met—for
example, according to the size or position of the lesion,
persistence, and when adequate follow-up cannot be
guaranteed.12 16Although the guidelines argue for a conservative
approach to treatment of small grade 2 lesions in young women,
those with histologically confirmed grade 2 and grade 3 lesions
are in general immediately treated. These women are
recommended for cytological follow-up at six, 12, and 24
months. If any follow-up smear test result is at least borderline
dyskaryotic, the women are recommended to undergo
colposcopy. If the recommended three consecutive follow-up
smear tests all provide normal results, the women are
recommended to rejoin the regular screening programme, with
repeat testing at five yearly intervals from age 30 to 60 years.12
After treatment of adenocarcinoma in situ, however, women
remain in intensified follow-up for five years.
Data source
We retrieved data on all cervix uteri cytological and histological
tests in the Netherlands registered until 31 March 2007 from
the Dutch nationwide network and register of histopathology
and cytopathology (PALGA).17 This registration began in the
1970s and has had virtually complete (about 99%) coverage of
pathology laboratories since 1991.18 19 The pathology register
is used primarily for revealing the total individual history of
pathological investigations to pathologists when evaluating
tissue or cells. It contains diagnoses that were communicated
to treating doctors, and therefore reflects the clinical practice.
During the period investigated, Dutch laboratories used
predominantly conventional cytology.
In the pathology register, women are identified by their sex,
birth date, and the first four letters of their maiden name. This
identification string enables the linkage of different tests
belonging to the same woman, and therefore also to follow
individual testing histories (dates and diagnoses). We avoided
the problem of false identity matches, which is present with
such identification,20 by excluding women with 0.5% of the
most common four letter combinations in maiden names, which
corresponds to excluding about 30% of women.21 Wemade the
reasonable assumption of no association between the measures
we were interested in and having a common maiden name. A
comparison with the laboratory data from Screening Region
West of the Netherlands, in which the identification is complete,
suggested that our method of excluding women with 0.5% of
the most common surnames is adequate for calculating relative
indicators.22
Definition of cervical cancer
We identified women with cervical cancer by selecting excerpts
that included pathology codes for cervical cancer based on the
Systematised Nomenclature of Medicine.18 These codes are
sometimes also used for lesions that are not clearly invasive, or
when there is doubt that the primary location was the cervix.
Consequently, based on these codes the number of women with
incident cervical cancer seems substantially higher than the
number recorded in the Netherlands cancer registry. For women
with cervical cancer codes in the pathology register between 1
January 1994 and 31 December 2006, we reviewed the
conclusions (free text) of all registered histology reports. In case
the codes differed from the pathologist’s conclusion, we used
the latter. A comparison with the data from the Netherlands
cancer registry showed that after this review our edited
pathology register data contained about 7% more cases of
cervical cancer than the Netherlands cancer registry. The excess
incidence in our data, however, was not clustered in a particular
calendar year and it was observed in all age groups up to 75
years.22
Definition of a primary test
We defined a primary test as a non-secondary test. A secondary
or follow-up test was defined as a histological or a cytological
test taken within four years after a previous abnormal or
inadequate test result, unless follow-up of the abnormal or
inadequate test result had already been completed according to
the guidelines.12 23We defined an abnormal test result as at least
borderline dyskaryosis on cytology and its equivalent on
histology. Completed follow-up would be, for example, two
consecutive normal smear test results after a borderline
dyskaryotic result, or three consecutive normal smear test results
after histologically confirmed cervical intraepithelial neoplasia.
We considered smear test results registered shortly after a
previous smear test (≤4 days) as duplicates, and these were
excluded. By using these definitions we organised registered
individual screening histories into testing episodes. An episode
was defined as starting with a primary test (a smear or a biopsy)
followed by secondary tests in case the primary smear test result
was abnormal. Thus an episode lasted for one test if the primary
test result was normal, otherwise until the follow-up was
completed according to the guidelines, or if four years had
passed since the last test.
Definition of completed negative follow-up of
histologically confirmed cervical
intraepithelial neoplasia
We identified all episodes with histologically confirmed cervical
intraepithelial neoplasia grades 1, 2, or 3 and no cervical cancer
diagnosis, and thereafter classified the episodes according to
the maximum diagnostic grade within the episode. Type of
treatment is not registered consistently in the pathology register
and could therefore not be used in the analysis. In the main
analysis, we considered all episodes of cervical intraepithelial
neoplasia that ended with three consecutive normal smear test
results—that is, completed negative test results at follow-up
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(figure⇓). This was also the case for cervical intraepithelial
neoplasia grade 1, although the guidelines recommended only
one follow-up smear test. If new abnormal test results were
encountered after the initial histological diagnosis of cervical
intraepithelial neoplasia, we reset the counting of consecutive
normal smear test results to zero. In a side analysis, we
considered episodes of cervical intraepithelial neoplasia with
completed negative test results at follow-up only if the timing
of testing followed the recommendations. We allowed delays
of up to six months at each step. In this side analysis, the third
consecutive normal smear test result must have been registered
between 18 months (an accepted minimum) and 42 months (24
months recommended for follow-up plus three delays of six
months accepted at most) after the last abnormal smear test or
biopsy result within the episode.
Statistical analysis
We observed the incidence of cervical cancer after completion
of negative post-treatment follow-up compared with the
incidence after any normal primary smear test. Woman years
at risk were counted from the primary test of the current episode
onwards. At present in the Netherlands invitations for screening
are sent at fixed five year intervals when women turn 30, 35,
40, 45, 50, 55, and 60 years, and relatively few smears are taken
outside of the screening programme.24 Counting the woman
years from the primary test onwards therefore theoretically
ensured that the next screening round after episodes of cervical
intraepithelial neoplasia and after episodes with normal primary
smear test results would coincide on average in about five years.
The counting of woman years ended at the date of the first
histologically proved diagnosis of cervical cancer if it was
diagnosed in the next episode (cases), or otherwise at the
primary test of the next episode, 31 December 2006, or on
completion of a 10 year period, whichever came first. We
censored the follow-up at 10 years because few woman years
accrued beyond that period. The woman years at risk for
episodes with completed negative test results at follow-up are
represented by a+b in the figure.
Because we manually checked all excerpts from the pathology
register with the cervical cancer codes in the period between 1
January 1994 and 31 December 2006, the woman years at risk
and cervical cancer cases were left censored until 1 January
1994. We additionally left censored woman years at risk in the
episodes with cervical intraepithelial neoplasia (a in figure)
from the primary test until the third consecutive normal smear
test result because women were still being followed-up and no
cervical cancer was by definition diagnosed during that period.
Based on these data, we calculated the yearly incidence of
cervical cancer per 100 000 woman years at risk and calculated
95%Poisson confidence intervals using an exact method.25After
verifying that the yearly hazard ratios did not differ significantly,
we calculated the 10 year overall hazard ratios by Cox regression
with yearly follow-up intervals, and we corrected for year in
follow-up. We did not additionally correct the hazard ratios for
age at primary smear test because the numbers of diagnosed
cervical cancers by age group (grouped as ≤29 years, 30-49
years, and ≥50 years) were small. The hazard ratios were
calculated with R version 2.7.1.
Results
In total, 38 956 episodes with histologically confirmed cervical
intraepithelial neoplasia were completedwith negative follow-up
test results (table 1⇓). For these episodes a primary smear test
was taken at a mean age of 35.9 (SD 8.6) years. On average,
4.9 years of follow-up were available per episode during the
first 10 years after the primary test. Of these, 3.4 years were left
censored (accrued before the end of follow-up, or before 1994),
leaving on average 1.5 woman years after the third consecutive
normal smear test result available for the analysis. In total, 20
cases of cervical cancer were diagnosed in 56 956 woman years
in the analysis. The 7 096 816 primary smear tests with normal
results were taken at a mean age of 41.9 (SD 10.9) years. On
average, 4.1 years of follow-up accrued in the first 10 years for
these smear tests, with 3.5 years on average available for
analysis after left censoring of woman years before 1994. During
the 25 020 697 woman years available for the analysis, 1613
cases of cervical cancer were diagnosed.
For women with completed negative follow-up test results after
histologically proved cervical intraepithelial neoplasia, the
yearly incidence of cervical cancer until the next episode were
consistently increased comparedwith womenwith normal smear
test results (table 2⇓). The resulting 10 year hazard ratios were
significantly increased in all three age groups, and the overall
hazard ratio was 4.2 (95% confidence interval 2.7 to 6.5, table
3⇓). The results were not materially changed by including only
the 23 415 episodes of cervical intraepithelial neoplasia in which
the timing of the normal test results followed the
recommendations (38 040 woman years at risk and 13 cases of
cervical cancer; footnote to table 1). In this case, the 10 year
hazard ratio was 4.0 (2.3 to 6.9).
For the comparison of the risk by grade of cervical intraepithelial
neoplasia (table 4⇓), among the 38 956 episodes with completed
negative follow-up test results, in 8837 episodes (23%) the most
severe diagnosis was cervical intraepithelial neoplasia grade 1,
in 9020 episodes (23%) it was grade 2, and in 21 099 episodes
(54%) it was grade 3. The 10 year hazard ratio of cervical cancer
after detection of grade 1 compared with grade 3 lesions was
1.3 (95% confidence interval 0.4 to 3.7) and after detection of
grade 2 compared with grade 3 lesions was 1.4 (0.5 to 4.2).
Discussion
Compared with women with normal primary smear test results
the overall risk of cervical cancer in women who had three
consecutive normal smear test results during post-treatment
follow-up for cervical intraepithelial neoplasia was increased
fourfold (35 cases per 100 000 woman years). This increased
risk could be observed regardless of the woman’s age and the
grade of neoplasia. These results have implications for women
treated for cervical intraepithelial neoplasia, although how the
excess risk could be decreased is not straightforward.
Limitations and strengths of the study
Our analysis has some limitations. Firstly, owing to incomplete
registration of the treatments we were not able to determine
how many women with cervical intraepithelial neoplasia were
treated. Nevertheless, Dutch guidelines recommend treatment
of cervical intraepithelial neoplasia grade 3 and, with some
exceptions, grade 2 lesions, and watchful waiting with treatment
if necessary for grade 1 lesions.12 16 Histological confirmation
of cervical intraepithelial neoplasia, treatment, and follow-up
smear tests are all undertaken by gynaecologists. The fact that
women had completed post-histology follow-up with three
smear tests may therefore suggest that the women received not
only follow-up according to the recommendations but also
treatment (including watchful waiting in the case of cervical
intraepithelial neoplasia grade 1). In support of this assumption,
we estimated from several Dutch national databases that nearly
all women with grade 2 and grade 3 lesions must have been
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treated and that about 40% of women with grade 1 lesions must
have been treated at some time.26 Secondly, although this was
also one of the strengths of our analysis, we focused on
determining the risk of cervical cancer in womenwith completed
negative follow-up test results after a diagnosis of cervical
intraepithelial neoplasia, whereas we did not determine the risk
in women with incomplete follow-up.3 27 A correct assessment
of their risk would require adjustments in study methods, and
should be dealt with in a separate analysis.
Our analysis has other important strengths. Firstly, to our
knowledge this is the first study to focus on women who
completed the post-treatment follow-up according to a particular
set of recommendations. We have learnt that the excess risk of
cervical cancer after treatment of cervical intraepithelial
neoplasia cannot be fully explained by lack of post-treatment
follow-up. An earlier large population based study from British
Columbia provided an estimate of the risk of cervical cancer in
women who were under active surveillance—that is, they had
at least one smear test carried out in a three year period,
compared with all women after treatment of cervical
intraepithelial neoplasia.5 Unlike in our study, a separate risk
estimate was not presented for women who completed the
recommended sequence of normal smear tests and could rejoin
the routine screening programme. Secondly, we used a national
population based pathology register with virtually complete
coverage since 1991 and could therefore identify all women
with cervical intraepithelial neoplasia and determine their
follow-up histories. Thirdly, although our study was not the
only one to do so, we used cervical cancer as the endpoint
instead of cervical intraepithelial neoplasia or cervical cancer
(typically with few cases of cancer). Our research group has
shown that in evaluation of primary cervical screening using
cervical intraepithelial neoplasia as the endpoint can give a
substantially different estimate of the relative risk than using
cervical cancer as the endpoint.28 This also seems to be the case
after treatment.Without selecting on completed follow-up, other
researchers have consistently shown that whereas the risk of
residual or recurrent cervical intraepithelial neoplasia declines
to the background level after the first few years after treatment,
the risk of cervical cancer stays higher than in the background
level.3 5 The same kind of contrast could be seen in the
Netherlands. A recent study of 435 women with cervical
intraepithelial neoplasia treated at three major hospitals or (a
minority) randomised to condom use instead of being treated
showed a virtually equal risk of cervical intraepithelial neoplasia
grade 2 or worse after three consecutive normal post-treatment
smear test results compared with women with normal cytology
in population based screening. The logical conclusion of that
study was to return women with completed negative follow-up
test results to routine screening.19 Our study, however, found a
continuing excess risk of cervical cancer until the next episode,
suggesting an additional degree of complexity in decision
making for women after treatment.
Comparison with earlier studies
The fourfold hazard ratio of cervical cancer in our study was
higher than similar estimates in several other studies, in which
the relative risk was typically less than three.2-4 6 This difference
can to some extent be explained by the types of comparison
groups used. Many previous studies used the incidence in local
general populations, including screened and unscreened women
as the comparison. Had we also compared the incidence in
treated women with that in the general population (about 12.5
per 100 000 for women aged 25 to 64 years in 1994 to 2006,
which represents the age range of 90% of the episodes included
in our analysis along with about 10 years thereafter),29 30 our
estimate of the fourfold excess risk would be about halved. On
the other hand, the study fromBritish Columbia found a relative
risk of about six, comparing with women at very low risk with
at least three consecutive normal smear test results and no
history of cervical intraepithelial neoplasia.5
Although the risk of cervical intraepithelial neoplasia
progressing to cancer increases with increasing grade of
neoplasia,31 in our data the risk of cervical cancer in women
with treated grade 3 lesions did not seem to be higher than
among women with treated grade 1 or 2 lesions. This
corroborated the earlier findings from Finland.32 These results
can be interpreted in several ways. Firstly, they could reflect a
less aggressive clinical management of cervical intraepithelial
neoplasia grades 1 and 2. However, some cervical intraepithelial
neoplasia grade 1 and virtually all grade 2 lesions tend to be
treated,26 33 and even without treatment they are often
regressive.31 34 Secondly, the incidence of cervical cancer after
cervical intraepithelial neoplasia observed in our study, of about
35 per 100 000 woman years (table 2) is low compared with the
observed progression rates of untreated cervical intraepithelial
neoplasia grade 3 to cervical cancer, which is about 30% in 30
years.35 Therefore our data probably point to high effectiveness
of the current clinical management of high grade cervical
intraepithelial neoplasia in reducing the risk of cervical cancer.
Causes of continued excess risk for cervical
cancer
Dutch recommendations requiring three consecutive normal
smear test results before a treated woman can rejoin the routine
screening programme are, internationally, some of the least
intensive. Therefore it would be interesting to determine whether
any additional normal smear test results beyond the third could
help treated women in catching up with the low risk observed
in women with normal primary smear test results. To study the
risk of cervical cancer in the period after the subsequent normal
primary smear test result, we used the same methodology as for
the main analysis (see supplementary file). Among the 38 956
women in our main analysis, only 8% had no additional normal
smear test results; 23% had one, 18% had two, and 52% had at
least three. In total, 39 cervical cancers were diagnosed in 232
428 woman years at risk, compared with 1226 cervical cancers
in 20 571 145 woman years in the 5 646 137 episodes with
normal primary smear test results without any previous
abnormality. The resulting 10 year hazard ratio after additional
normal smears was 3.6 (95% confidence interval 2.6 to 5.0),
which is only slightly lower than the hazard ratio of 4.2 after
three consecutive normal smears test results (table 3). This is
despite the fact that after having completed the recommended
follow-up, women with previous cervical intraepithelial
neoplasia continued to undergo cervical testing more often than
untreated women (on average every 1.9 years versus every 4.3
years). If anything, the contrast in the risk of cervical cancer
would be larger if the Netherlands used shorter screening
intervals. The risk after routine screening with shorter intervals
would be expected to be modestly lower,36whereas the risk after
treatment would be expected to be the same.
These puzzling additional data from women with intensive
follow-up emphasise the need to investigate the causes of the
excess risk of cervical cancer after treatment of cervical
intraepithelial neoplasia. These causes are at present poorly
understood and could not be evaluated directly in our study.
The excess risk might be a consequence of missed residual
neoplasia or of de novo incidence because treated women are
a selected high risk group. Firstly, residual neoplasia might be
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missed because changes in tissue after treatment may decrease
the sensitivity of cytology for cervical abnormalities. Two
meta-analyses, however, evaluated cytology and human
papillomavirus testing in primary screening and as follow-up
after treatment of cervical intraepithelial neoplasia.37 The
sensitivity of cytology for high grade cervical intraepithelial
neoplasia seemed comparable in the two situations. Furthermore,
detection of cervical cancer at an earlier stage in screened
women than in the general population is one of the indicators
of effective cervical screening. In the British Columbia study,
for example, 77% of cervical cancers diagnosed after treatment
of cervical intraepithelial neoplasia were stage 1, compared with
53% diagnosed at stage 1 in the general population in the United
States between 1998 and 2003.5 These findings suggest that
after treatment of cervical intraepithelial neoplasia, cytology is
similarly sensitive for early cancer as in primary screening.
Nevertheless, the findings cannot rule out a possibility that some
of the cervical cancers in women with several consecutive
normal smear test results in our study developed from
systematically missed residual lesions. If this is correct, then
the use of more sensitive follow-up tests might have reduced
the incidence of cervical cancer. Secondly, cervical cancers
diagnosed after completed follow-upmay have developed from
de novo lesions because women treated for cervical
intraepithelial neoplasia might have a higher background risk
than the general population. Characteristics of women or their
partners (for example, more frequent reinfections with human
papillomavirus) or problems with the woman’s immune system
(for example, a relatively low capability to clear the infection
compared with the general population) would lead to more
frequent newly developed progressive cervical intraepithelial
neoplasia. In this case, treated womenmay have benefitted from
the more frequent screening observed in our data, and might
further benefit from continued frequent screening.
Amulticohort study observed the long term incidence of cervical
intraepithelial neoplasia grade 2 or worse in Dutch women who
were followed-up by frequent cytology and human
papillomavirus testing for two years after treatment and then
rejoined routine screening. Five to 21 years after treatment, 13%
of these women had a human papillomavirus infection,19
compared with about 4-5% in the general Dutch population.38
The higher prevalence of infections seems compatible with both
the residual lesions and the de novo incidence hypotheses. The
study furthermore suggested that lesions may be picked up better
by human papillomavirus testing than by cytology, in that fewer
human papillomavirus tests would be needed to obtain the same
protection as with cytology.19 This may mean that turning to
human papillomavirus testing may be more efficient and
possibly more effective than intensifying cytological follow-up.
Because of relatively frequent positive human papillomavirus
test results without underlying dysplasia, however, management
of women with positive test results should be studied carefully.
Follow-up recommendations after treatment
Frequent follow-up with cytology is justifiable in the first two
to three years after treatment, when most residual cervical
intraepithelial neoplasia tends to be picked up.5 19 After having
observed that women remain at increased risk of cervical cancer
for a long time after treatment, several authors have proposed
that such women should be kept in long term frequent follow-up,
ranging from 10 to 25 years,3-5 although the current trend in
some European countries has been more towards shorter rather
than longer follow-up. Our study alone, however, cannot give
a straightforward answer to what should be recommended in
the longer term. Several factors should be taken into account
when deciding on the optimal length of post-treatment
follow-up. In our study, treated women continued to be screened
at short intervals, which may have helped reduce their burden
of cervical cancer to an unknown degree. Although the
remaining absolute risk observed from the third consecutive
negative smear test result after treatment until the next episode
(35 per 100 000 woman years) was four times higher than in
women without previous detection of cervical intraepithelial
neoplasia, it was still low. Finally, the absolute risk of cervical
cancer is expected to decrease in the coming decades as human
papillomavirus based screening is routinely introduced, and
substantial proportions of young birth cohorts are currently
being vaccinated against two major carcinogenic human
papillomavirus genotypes. As a consequence, we expect a
reduction in the risk of cervical cancer after routine screening,
and the number of women with treated cervical intraepithelial
neoplasia may also decrease.
To determine the most optimal management, modelling is often
used. Modelling may be helpful in exploring the consequences
of the different hypotheses on the determinants of the observed
excess risk. However, as we do not have conclusive data on
why treated women are at increased risk despite relatively
frequent screening, an effective and still efficient follow-up
strategy cannot be derived from modelling. Only a randomised
controlled trial embedded in a screening programme could give
amore conclusive answer, although such a trial would probably
necessitate inclusion of a prohibitive number of women.
In conclusion, an excess risk of cervical cancer that has been
previously observed for the complete group of women treated
for cervical intraepithelial neoplasia could also be observed in
the subgroup of women who completed their post-treatment
follow-up with three consecutive normal smear test results.
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What is already known on this topic
Treatment of screen detected cervical intraepithelial neoplasia is highly effective in preventing development of cervical cancer
Treated women nevertheless remain at higher risk of cervical cancer than untreated women, and this could be due to lack of post-treatment
follow-up
What this study adds
Regardless of women’s age and grade of cervical intraepithelial neoplasia, the risk of cervical cancer after completed post-treatment
follow-up (35 per 100 000 woman years) remained about four times higher than in women with normal primary smear test results
The excess risk after treatment of cervical intraepithelial neoplasia cannot be fully explained by lack of post-treatment follow-up
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Tables
Table 1| Size of study groups
No of cases*No of woman years at risk*No of episodes
Mean (SD) age at primary smear
test (years)Type of episode
20‡56 95638 95635.9 (8.6)CIN with completed negative
follow-up test results†
161325 020 6977 096 81641.9 (10.9)Normal primary smear test results
CIN=histologically confirmed cervical intraepithelial neoplasia.
*Only non-censored woman years at risk are included.
†When episodes of CIN with completed negative follow-up results were considered only if the timing of follow-up tests followed recommendations (side analysis),
13 cases of cervical cancers were diagnosed in 38 040 woman years within 23 415 episodes that started at an mean age of 36.0 (SD 8.6) years.
‡One woman was treated for adenocarcinoma in situ.
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Table 2| Yearly incidence rates of cervical cancer after completed negative follow-up results of histologically confirmed cervical intraepithelial
neoplasia (CIN) and after normal primary smear test results
Normal primary smear test resultsCIN with completed negative follow-up test resultsInterval (years)
after primary
smear test
Incidence per 100 000
woman years (95% CI)No of casesWoman years
Incidence per 100 000
woman years (95% CI)No of casesWoman years
4.6 (4.1 to 5.2)2525 442 5390 (0 to 4853.8)0760 to 1
4.0 (3.5 to 4.6)1944 829 8870 (0 to 109.3)033761 to 2
4.7 (4.0 to 5.4)1944 158 76221.0 (2.5 to 75.7)295412 to 3
6.5 (5.7 to 7.4)2133 277 69826.4 (5.4 to 77.2)311 3583 to 4
9.2 (8.1 to 10.5)2262 451 79429.7 (6.1 to 86.7)310 1154 to 5
15.4 (13.4 to 17.6)2211 433 68070.1 (22.8 to 163.5)571355 to 6
10.3 (8.4 to 12.4)1111 081 69874.1 (20.2 to 189.7)453996 to 7
9.3 (7.4 to 11.5)85916 11722.9 (0.6 to 127.4)143727 to 8
7.3 (5.6 to 9.5)57776 85561.1 (7.4 to 220.8)232728 to 9
9.2 (7.0 to 11.9)60651 6660 (0 to 159.6)023119 to 10
6.4 (6.1 to 6.8)161325 020 69735.1 (21.4 to 54.2)2056 956Total*
*Total hazard ratio comparing incidence rates of cervical cancer 35.1 per 100 000 woman years at risk and 6.4 per 100 000 woman years at risk, corrected for
year in follow-up, was 4.2 (95% confidence interval 2.7 to 6.5; table 3).
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Table 3| Ten year hazard ratios of developing cervical cancer after negative follow-up test results following histologically confirmed cervical
intraepithelial neoplasia, by age group
Hazard ratio* (95% CI)No of casesWoman years at riskAge (years) at primary smear test
5.2 (2.3 to 11.7)612 579≤29
3.2 (1.8 to 5.6)1239 16530 to 49
6.8 (1.7 to 27.3)25212≥50
4.2 (2.7 to 6.5)2056 956Total
*Compared with normal primary smear test results (see tables 1 and 2). Corrected for year in follow-up.
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Table 4| Ten year hazard ratios of developing cervical cancer after negative follow-up test results following histologically confirmed cervical
intraepithelial neoplasia (CIN), for grades 1 and 2 lesions compared with grade 3
Hazard ratio* (95% CI)No of casesWoman years at riskGrade of CIN
1.3 (0.4 to 3.7)614 4821
1.4 (0.5 to 4.2)613 7522
1 (reference)828 7223
—2056 956Total
*Corrected for year in follow-up.
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Figure
Definition of completed negative test results at follow-up after histologically confirmed cervical intraepithelial neoplasia and
counting of woman years at risk for a hypothetical episode. CIN=histologically confirmed cervical intraepithelial neoplasia.
a=left censored (excluded) woman years at risk because of ongoing follow-up during which by definition no cervical cancer
was diagnosed; b=included woman years at risk. Because for all episodes woman years at risk were also left censored
before 1 January 1994, episodes of cervical intraepithelial neoplasia with completed negative follow-up test results were
included in the analysis if at least part of b accrued after that date. Restrictions for side analysis (episodes of cervical
intraepithelial neoplasia in which follow-up testing followed recommended timing): c=maximum 12 months (recommended
six months and an allowed delay of six months); d=18 to 42 months
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